Australia's TGA approves the first weight-loss pill, oral semaglutide (Wegovy)
- Australia's Therapeutic Goods Administration has approved a once-daily oral tablet form of semaglutide, sold as Wegovy.
- It is registered in 1.5 mg, 4 mg, 9 mg and 25 mg strengths for chronic weight management and to reduce cardiovascular risk in eligible adults.
- The TGA advises against combining Wegovy tablets or injections with other semaglutide products or other GLP-1 drugs.
- The tablet is not yet available in Australia, and it has no subsidy on the Pharmaceutical Benefits Scheme.
Australia's medicines regulator, the Therapeutic Goods Administration (TGA), has approved the country's first weight-loss pill: a once-daily oral tablet form of semaglutide sold as Wegovy. According to newsGP, the publication of the Royal Australian College of General Practitioners, the approval was granted on Tuesday 3 November 2026.
What was approved
The tablet is registered in 1.5 mg, 4 mg, 9 mg and 25 mg strengths. A TGA spokesperson said its indications, chronic weight management and reducing the risk of major adverse cardiovascular events in eligible adults, match those of the injectable Wegovy. The TGA warned that using Wegovy tablets or injections together with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended.
Also read: EMA recommends Foundayo (orforglipron), a once-daily GLP-1 tablet for obesity and type 2 diabetes
How it is taken
Because semaglutide is poorly absorbed from the gut, the tablet must be swallowed on an empty stomach with a sip of water on waking, followed by a 30-minute wait before eating, drinking or taking other oral medicines, according to the US product information.
Access questions
RACGP President Dr Michael Wright called the approval "a step forward" for patients who avoid injections, but stressed that GLP-1 medicines can have serious side effects and are best prescribed by a regular GP alongside advice on diet and exercise. Novo Nordisk says it expects availability later this year. The tablet is not subsidised, and injectable Wegovy is also still not listed on the Pharmaceutical Benefits Scheme despite a recommendation almost a year ago.
Data cited by newsGP suggest about 1.6 million Australians bought a GLP-1 medicine privately in the past 12 months.
Source: newsGP (RACGP)
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
Has Australia approved a weight-loss pill?
Yes. Australia's Therapeutic Goods Administration approved an oral once-daily tablet form of semaglutide, sold as Wegovy, in November 2026.
What doses of the Wegovy pill were approved in Australia?
The TGA registered Wegovy tablets in 1.5 mg, 4 mg, 9 mg and 25 mg strengths.
How should the Wegovy pill be taken?
According to US product information, the Wegovy tablet is taken on waking on an empty stomach with a sip of water, followed by a 30-minute wait before eating, drinking or taking other oral medicines.
Can Wegovy tablets be combined with other GLP-1 drugs?
No. The TGA says using Wegovy tablets or injections together with other semaglutide products or other GLP-1 receptor agonists is not recommended.
Is the Wegovy pill subsidised in Australia?
No. The Wegovy pill is not subsidised in Australia, and injectable Wegovy is also not yet listed on the Pharmaceutical Benefits Scheme.



